Search Within

Aaron David Goldberg

Formats
  1. Meeting Abstract (61)
  2. Journal Article (30)
  3. Research Letter (6)
  4. Correspondence (3)
  5. Editorial (3)
  6. Review (2)
  7. Book Section (1)
Groups
  1. Adult Leukemia (106)
  2. Center for Hematologic Malignancies (106)
  3. Department of Medicine (106)
  4. Hematologic Malignancies, Division of (106)
  5. Weinberg Fellows (106)
  6. Hematology-Oncology Fellows (48)

More Groups

People
  1. Martin Tallman (46)
  2. Eytan Stein (38)
  3. Christopher Famulare (36)
  4. Ross Levine (20)
  5. Jan Bewersdorf (19)
  6. Andriy Derkach (18)

More People

Years
  1. 2025 (2)
  2. 2024 (11)
  3. 2023 (20)
  4. 2022 (15)
  5. 2021 (15)
  6. 2020 (15)

More Years

Publications
  1. Blood (55)
  2. Leukemia and Lymphoma (8)
  3. American Journal of Hematology (6)
  4. Blood Advances (5)
  5. Journal of Clinical Oncology (5)
  6. Haematologica (4)

More Publications

Publishers
  1. American Society of Hematology (60)
  2. Taylor & Francis Group (8)
  3. American Society of Clinical Oncology (6)
  4. John Wiley & Sons, Inc. (5)
  5. Ferrata Storti Foundation (4)
  6. Nature Publishing Group (4)

More Publishers

Results (106)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • KOMET-008: A phase 1 study to determine the safety and tolerability of ziftomenib combinations for the treatment of KMT2A-rearranged or NPM1-mutant relapsed/refractory acute myeloid leukemia
    Meeting Abstract

    Goldberg, A. D.; Corum, D.; Ahsan, J.; Nie, K.; Kozlek, T.; Leoni, M.; Dale, S.
    Blood (2023)

    Fulltext@MSK | Save
  • Despite high rates of remission, treatment of IDH-mutant AML with hypomethylating agents and venetoclax is associated with frequent treatment delays, modifications, and transfusions
    Meeting Abstract

    Chin, K. K.; Derkach, A.; Famulare, C.; Gupta, G.; Borge, P.; Berman, E.; Geyer, M. B.; Goldberg, A. D.; Haque, T.; Rampal, R. K.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Real-world transfusion independence among newly diagnosed acute myeloid leukaemia patients receiving venetoclax combinations versus other therapies
    Meeting Abstract

    Wolach, O.; Garcia, J.; Vachhani, P.; Zeidner, J.; Lai, C.; Moshe, Y.; Xavier, M.; Lee, S.; Zuckerman, T.; Pollyea, D.; more...
    British Journal of Haematology (2023)

    Fulltext@MSK | Save
  • Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia
    Journal Article

    McCarter, J. G. W.; Nemirovsky, D.; Famulare, C. A.; Farnoud, N.; Mohanty, A. S.; Stone-Molloy, Z. S.; Chervin, J.; Ball, B. J.; Epstein-Peterson, Z. D.; Arcila, M. E.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save
  • Single-cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia
    Journal Article

    Robinson, T. M.; Bowman, R. L.; Persaud, S.; Liu, Y.; Neigenfind, R.; Gao, Q.; Zhang, J.; Sun, X.; Miles, L. A.; Cai, S. F.; more...
    Science Advances (2023)

    Fulltext@MSK | Save
  • Implementing a germline testing program using fingernail specimens for patients with hematologic malignancies and initial clinical findings
    Meeting Abstract

    Walsh, M. F.; Fiala, E.; Birsoy, O.; Haque, T.; Stein, E. M.; Shukla, N.; Sulis, M. L.; Goldberg, A. D.; Rana, S.; Khurram, A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Phase 1 study of PRT1419 (MCL1 inhibitor) as monotherapy or in combination with azacitidine or venetoclax in patients with relapsed/refractory myeloid or B‐cell malignancies
    Meeting Abstract

    Zuniga, R. R.; Nair, S.; Keiffer, G.; Ravandi‐Kashani, F.; Goldberg, A. D.; Traer, E.; Frenzel, L. P.; Röllig, C.; Savickas, G.; Sun, W.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: Results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
    Journal Article

    Badar, T.; Atallah, E.; Shallis, R.; Saliba, A. N.; Patel, A.; Bewersdorf, J. P.; Grenet, J.; Stahl, M.; Duvall, A.; Burkart, M.; more...
    Leukemia (2023)

    Fulltext@MSK | Save
  • Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: A phase 1, dose-finding and expansion study
    Journal Article

    Garcia-Manero, G.; Goldberg, A. D.; Winer, E. S.; Altman, J. K.; Fathi, A. T.; Odenike, O.; Roboz, G. J.; Sweet, K.; Miller, C.; Wennborg, A.; more...
    The Lancet Haematology (2023)

    Fulltext@MSK | Save
  • Safety and efficacy of CPX-351 in younger patients (<60 years old) with secondary acute myeloid leukemia
    Research Letter

    Przespolewski, A.; Goldberg, A. D.; Talati, C.; Fazal, S.; Vachhani, P.; Sanikommu, S. R.; Thota, S.; Waksal, J.; Ball, B.; Famulare, C.; more...
    Blood (2023)

    Fulltext@MSK | Save